Chengdu Kanghong Pharmaceutical Co. Ltd. has identified DNA polymerase θ (POLθ) inhibitors reported to be useful for the treatment of cancer.

Chengdu Kanghong Pharmaceutical Co. Ltd. has described orexin OX2 receptor (OX2R; HCRTR2) antagonists reported to be useful for the treatment of secondary insomnia and major depression.

Chengdu Kanghong Pharmaceutical Co. Ltd. has synthesized indazolinone compounds acting as glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of cardiovascular disorders, cerebral infarction, dementia, diabetes, hyperlipidemia, metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis [NASH]), obesity and stroke.

Chengdu Kanghong Pharmaceutical Co. Ltd. has disclosed sodium channel protein type 10 subunit alpha (Nav1.8) channel blockers reported to be...